Evolving novel anti-HER2 strategies
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference76 articles.
1. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases;Beatson;Lancet,1896
2. HER2-targeted therapy in breast cancer: monoclonal antibodies and tyrosine kinase inhibitors;Nielsen;Cancer Treat Rev,2009
3. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer;Valabrega;Ann Oncol,2007
4. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients;Nagata;Cancer Cell,2004
5. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941;Junttila;Cancer Cell,2009
Cited by 101 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA);American Heart Journal Plus: Cardiology Research and Practice;2024-04
2. Cancer treatment with biosimilar drugs: A review;Cancer Innovation;2024-04
3. Inhibiting HER3 Hyperphosphorylation in HER2‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells;Small;2023-08-26
4. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer;Biomedicine & Pharmacotherapy;2023-06
5. Pharmacogenetics of Anticancer Drugs: Clinical Response and Toxicity;Therapeutic Approaches in Cancer Treatment;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3